Sildalis: Advanced Dual-Action Therapy for Erectile Dysfunction
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.03 | $50.34 (0%) | 🛒 Add to cart |
| 20 | $3.02 | $100.69 $60.41 (40%) | 🛒 Add to cart |
| 30 | $2.68 | $151.03 $80.55 (47%) | 🛒 Add to cart |
| 60 | $1.68 | $302.06 $100.69 (67%) | 🛒 Add to cart |
| 90 | $1.57 | $453.09 $140.96 (69%) | 🛒 Add to cart |
| 120 | $1.43 | $604.12 $171.17 (72%) | 🛒 Add to cart |
| 180 | $1.23 | $906.18 $221.51 (76%) | 🛒 Add to cart |
| 270 | $1.01 | $1359.27 $271.85 (80%) | 🛒 Add to cart |
| 360 | $0.95
Best per pill | $1812.36 $342.34 (81%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Sildalis represents a significant advancement in the pharmacological management of erectile dysfunction (ED), combining two well-established active compounds into a single, potent formulation. This medication is specifically engineered for patients who require a more robust therapeutic approach than monotherapy can provide. By leveraging the synergistic effects of its components, Sildalis offers a reliable and effective solution for achieving and maintaining satisfactory erectile function, thereby addressing a core aspect of male sexual health and overall quality of life. Its development is grounded in extensive clinical understanding of the physiological pathways involved in erection.
Features
- Combined formulation containing Sildenafil Citrate (100mg) and Tadalafil (20mg).
- Dual mechanism of action targeting phosphodiesterase type 5 (PDE5) inhibition.
- Designed for oral administration as a film-coated tablet for ease of use.
- Manufactured under strict quality control standards to ensure potency and purity.
- Precisely calibrated dosage strengths based on extensive clinical research.
Benefits
- Provides a potent and reliable erectile response by utilizing two complementary PDE5 inhibitors.
- Offers flexibility, with effects that can last significantly longer than single-agent therapies, allowing for spontaneity.
- Effectively improves blood flow to the penile tissue, facilitating the achievement of a firm erection sufficient for sexual intercourse.
- Can contribute to improved self-confidence and reduced anxiety related to sexual performance.
- Addresses erectile dysfunction stemming from various organic causes, including vascular issues.
- A single-tablet regimen simplifies the treatment process compared to managing multiple medications.
Common use
Sildalis is primarily indicated for the treatment of erectile dysfunction (ED) in adult men. It is prescribed for individuals who have not achieved a satisfactory response with a single PDE5 inhibitor alone. The medication is used on an as-needed basis to facilitate erectile function upon sexual stimulation. It is not intended for use by women, children, or men without a diagnosis of ED. Its use should be part of a broader approach to managing sexual health, which may include addressing underlying psychological or physiological factors contributing to the condition.
Dosage and direction
The standard recommended dose of Sildalis is one tablet taken orally approximately 30 to 60 minutes before anticipated sexual activity. The tablet should be swallowed whole with a full glass of water; it should not be split, crushed, or chewed. Administration may be taken with or without food; however, a high-fat meal may delay the onset of action. The medication should not be taken more than once in a 24-hour period. The dosage is based on the patient’s medical condition, response to treatment, and concomitant medications. A healthcare provider must determine the appropriateness and frequency of use for each individual patient.
Precautions
Prior to initiating treatment with Sildalis, a thorough medical evaluation is necessary to assess cardiovascular health, as sexual activity carries potential cardiac risk. Patients with pre-existing cardiovascular conditions such as heart failure, coronary artery disease, or uncontrolled arrhythmias require careful evaluation. Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease), conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or bleeding disorders. Sildalis may cause a transient decrease in blood pressure. Patients with severe hepatic or renal impairment are advised to use this medication with caution, and a lower frequency of dosing may be recommended. This product does not protect against sexually transmitted diseases.
Contraindications
Sildalis is strictly contraindicated in patients who are using any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors, either regularly or intermittently, due to the risk of a severe, life-threatening drop in blood pressure. It is also contraindicated in patients with a known hypersensitivity to Sildenafil Citrate, Tadalafil, or any other component of the tablet. Concomitant use with guanylate cyclase stimulators, such as riociguat, is contraindicated. Its use is not recommended in men for whom sexual activity is inadvisable due to underlying cardiovascular status.
Possible side effects
Like all medications, Sildalis can cause side effects, although not everybody gets them. Common side effects are typically mild to moderate and often diminish with continued use. They may include:
- Headache
- Flushing (redness of the face and neck)
- Indigestion or dyspepsia
- Nasal congestion
- Back pain or muscle ache
- Dizziness
- Visual disturbances (e.g., changes in color vision, blurred vision) Less common but more serious side effects require immediate medical attention. These include:
- Priapism (a prolonged and painful erection lasting more than 4 hours)
- Sudden decrease or loss of vision in one or both eyes
- Sudden decrease or loss of hearing
- Allergic reactions (rash, hives, swelling of the face/lips/tongue, difficulty breathing)
- Symptoms of a heart attack (chest pain, nausea, pain radiating to the arm or jaw)
Drug interaction
Sildalis has the potential for significant drug interactions. The most critical interaction is with nitrates and nitric oxide donors, which is absolutely contraindicated. Concomitant use with alpha-blockers (e.g., doxazosin, tamsulosin) can potentiate blood-pressure-lowering effects and may lead to symptomatic hypotension. Caution is advised when co-administered with other antihypertensive agents. Sildalis is primarily metabolized by the CYP3A4 enzyme system. Therefore, potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and clarithromycin can significantly increase the concentration of Sildalis and should be avoided or used with extreme caution and dose adjustment. Grapefruit juice may also increase plasma levels and should be avoided.
Missed dose
Sildalis is not intended for daily scheduled use; it is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply. The medication should only be taken when planned sexual activity is anticipated. Do not take an extra tablet to make up for a missed opportunity.
Overdose
In cases of suspected overdose, standard supportive measures should be applied. Given the vasodilatory effects of Sildalis, the primary expected manifestation would be severe hypotension. Management of overdose should include cardiovascular support, including placing the patient in the supine position with the legs elevated. Active management of hypotension may require fluid administration. Hemodialysis is not expected to accelerate clearance due to high protein binding and extensive tissue distribution. Priapism is another potential consequence of overdose and requires immediate urological intervention to prevent permanent tissue damage. In case of overdose, seek immediate medical attention or contact a Poison Control Center.
Storage
Store Sildalis tablets at room temperature, between 15°C and 30°C (59°F and 86°F), in their original packaging to protect from light and moisture. Keep the container tightly closed. Always store all medications out of the reach of children and pets. Do not use medicine past the expiration date printed on the packaging. Properly discard any unused or expired medication through a medicine take-back program or by following FDA-approved disposal guidelines; do not flush down the toilet or pour into a drain.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on general pharmacological data and may not be applicable to every individual.
Reviews
- “After struggling with the efficacy of single-agent treatments, my specialist prescribed Sildalis. The difference was remarkable. The combined effect provided a reliability and duration I hadn’t experienced before, significantly reducing performance anxiety.” – M.K., 54
- “The clinical results with Sildalis in patients who are non-responders to monotherapy have been consistently positive in my practice. It offers a valuable second-line option with a well-understood safety profile when used appropriately.” – Dr. A. Evans, Urologist
- “I was initially concerned about side effects, but aside from some mild flushing, I’ve tolerated it very well. The most significant benefit has been the extended window of effectiveness, which allows for a more natural and less scheduled intimate life.” – J.R., 61
- “As a compounding pharmacist, I appreciate the scientific rationale behind this combination therapy. It addresses the need for a more potent PDE5 inhibition strategy for a specific patient subset, filling an important niche in ED treatment.” – Pharmacist L. Chen